# 21 U.S.C. § 353a: Pharmacy compounding

> Federal · Statutes · In force

URL: https://www.frixlaw.com/law-library/statutes/usc_t21_s353a

## Section

- **Citation:** 21 U.S.C. § 353a
- **Heading:** Pharmacy compounding
- **Jurisdiction:** Federal
- **Kind:** Statutes
- **Status:** In force
- **Text as of:** April 17, 2026
- **Source:** Publisher's official text
- **Location:** Title 21—FOOD AND DRUGS > CHAPTER 9—FEDERAL FOOD, DRUG, AND COSMETIC ACT > SUBCHAPTER V—DRUGS AND DEVICES > Part A—Drugs and Devices

## Text

a licensed pharmacist in a State licensed pharmacy or a Federal facility, or

( June 25, 1938, ch. 675, § 503A , as added Pub. L. 105–115, title I, § 127(a) , Nov. 21, 1997 , 111 Stat. 2328 ; amended Pub. L. 113–54, title I, § 106(a) , Nov. 27, 2013 , 127 Stat. 598 .)

## Nearby sections

- [21 U.S.C. § 351 Adulterated drugs and devices](https://www.frixlaw.com/law-library/statutes/usc_t21_s351.md)
- [21 U.S.C. § 352 Misbranded drugs and devices](https://www.frixlaw.com/law-library/statutes/usc_t21_s352.md)
- [21 U.S.C. § 353 Exemptions and consideration for certain drugs, devices, and biological products](https://www.frixlaw.com/law-library/statutes/usc_t21_s353.md)
- [21 U.S.C. § 353a Pharmacy compounding](https://www.frixlaw.com/law-library/statutes/usc_t21_s353a.md)
- [21 U.S.C. § 353a–1 Enhanced communication](https://www.frixlaw.com/law-library/statutes/usc_t21_s353a%E2%80%931.md)
- [21 U.S.C. § 353b Outsourcing facilities](https://www.frixlaw.com/law-library/statutes/usc_t21_s353b.md)
- [21 U.S.C. § 353c Prereview of television advertisements](https://www.frixlaw.com/law-library/statutes/usc_t21_s353c.md)
- [21 U.S.C. § 353d Process to update labeling for certain generic drugs](https://www.frixlaw.com/law-library/statutes/usc_t21_s353d.md)
- [21 U.S.C. § 354 Veterinary feed directive drugs](https://www.frixlaw.com/law-library/statutes/usc_t21_s354.md)
- [21 U.S.C. § 355 New drugs](https://www.frixlaw.com/law-library/statutes/usc_t21_s355.md)
- [21 U.S.C. § 355–1 Risk evaluation and mitigation strategies](https://www.frixlaw.com/law-library/statutes/usc_t21_s355%E2%80%931.md)
- [21 U.S.C. § 355–2 Actions for delays of generic drugs and biosimilar biological products](https://www.frixlaw.com/law-library/statutes/usc_t21_s355%E2%80%932.md)
- [21 U.S.C. § 355a Pediatric studies of drugs](https://www.frixlaw.com/law-library/statutes/usc_t21_s355a.md)
- [21 U.S.C. § 355b Adverse-event reporting](https://www.frixlaw.com/law-library/statutes/usc_t21_s355b.md)

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/statutes/usc_t21_s353a. Check the current official text before relying on it. Not legal advice.